Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Hodgkin's Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    587 result(s) found for: Non-Hodgkin's Lymphoma. Displaying page 8 of 30.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2010-021091-28 Sponsor Protocol Number: AB10004 Start Date*: 2014-12-18
    Sponsor Name:AB Science
    Full Title: A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination...
    Medical condition: Relapsed or refractory Peripheral T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061871 Non-Hodgkin's lymphoma transformed recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) SK (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2005-004442-14 Sponsor Protocol Number: PEG UD0405 Start Date*: 2005-12-06
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI UDINE
    Full Title: A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and aut...
    Medical condition: Patients with - risk Non-Hodgkin's Lymphoma in complete or partial response who underwent autologous PBPC transplantation after high-dose chemiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012819 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004033-28 Sponsor Protocol Number: IPI-145-22 Start Date*: 2016-05-04
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects...
    Medical condition: Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002733-39 Sponsor Protocol Number: ML18324 Start Date*: 2005-04-06
    Sponsor Name:ROCHE
    Full Title: FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study.
    Medical condition: Previously untreated CD20-positive B-cell advanced indolent non follicular non-Hodgkin Lymphoma (NHL).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003371-29 Sponsor Protocol Number: FIL_ReRi Start Date*: 2016-09-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma. A phase II study of t...
    Medical condition: Diffuse Large B-cells non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003235-29 Sponsor Protocol Number: CC-99282-NHL-001 Start Date*: 2022-01-19
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE I/II, MULTI-CENTER, OPENLABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH ANTILYMPH...
    Medical condition: Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central ner...
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036685 Primary central nervous system lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001246-34 Sponsor Protocol Number: JCAR017-BCM-004 Start Date*: 2021-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A phase 1 / 2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL)
    Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL).
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000547-31 Sponsor Protocol Number: BGB-3111-LTE1 Start Date*: 2020-10-06
    Sponsor Name:BeiGene, Ltd.
    Full Title: An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B cell Malignancies
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003901 B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001966-27 Sponsor Protocol Number: AGB002 Start Date*: 2016-09-07
    Sponsor Name:Archigen Biotech Limited
    Full Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients w...
    Medical condition: Low Tumor Burden Follicular Lymphoma (LTBFL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) GB (Completed) CZ (Completed) BG (Completed) FR (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015974-36 Sponsor Protocol Number: REC-ANZ Start Date*: 2009-09-28
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: Phase II prospective study on high dose myeloablative therapy, with peripheral stem cell support, in elderly patients (>=65 e <76 years) with aggressive relapsed or refractory non Hodgkin lymphoma
    Medical condition: Aggressive relapsed or refractory non Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063908 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005851-15 Sponsor Protocol Number: GAINED Start Date*: 2013-05-13
    Sponsor Name:LYSARC
    Full Title: A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 OR RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATE...
    Medical condition: Patients with histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification), Aged ≥18 years and ≤60 years, with Age adjusted International Prognostic Index (aa-IPI) equal to 1, 2 or 3
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001088-38 Sponsor Protocol Number: BAY80-6946/17833 Start Date*: 2015-12-09
    Sponsor Name:Bayer AG
    Full Title: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in p...
    Medical condition: Patients with relapsed indolent non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Prematurely Ended) ES (Prematurely Ended) GB (Completed) FR (Completed) PL (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) HU (Completed) SK (Prematurely Ended) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001912-13 Sponsor Protocol Number: KTE-C19-105 Start Date*: 2018-04-24
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5)
    Medical condition: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (r/r) iNHL.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000771-33 Sponsor Protocol Number: LYSARC Start Date*: 2014-07-24
    Sponsor Name:LYSARC
    Full Title: BIBLOS (BTK Inhibition in B-cell LymphOmaS)
    Medical condition: Patients with any type of relapsed or refractory B-cell lymphoma will be eligible in groups A and B (during the dose escalation and the expansion parts of the study) and untreated patients with man...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003879-12 Sponsor Protocol Number: MK-0683 042-00 Start Date*: 2007-03-23
    Sponsor Name:Merck & Co., Inc.
    Full Title: Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma
    Medical condition: Cutaneous T-cell lymphoma (CTCL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) DK (Completed) FI (Completed) SI (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003230-17 Sponsor Protocol Number: MO28457 Start Date*: 2013-02-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DI...
    Medical condition: The target population will consist of adults with previously untreated CD20+ DLBCL or CD20+ follicular NHL Grade 1, 2 or 3a, according to the WHO classification system.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Completed) PT (Completed) SE (Completed) AT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001499-31 Sponsor Protocol Number: Epi-RCHOP Start Date*: 2016-08-09
    Sponsor Name:LYSARC
    Full Title: A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis treated by R-CHOP
    Medical condition: newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024215-14 Sponsor Protocol Number: C25001 Start Date*: 2012-11-06
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
    Medical condition: CD30-Positive Cutaneous T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000169-34 Sponsor Protocol Number: M20-638 Start Date*: 2022-10-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymp...
    Medical condition: Relapsed/Refractory Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085128 Follicular lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000409-19 Sponsor Protocol Number: TOTAL Start Date*: 2018-05-08
    Sponsor Name:LYSARC
    Full Title: A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance
    Medical condition: Relapsed or refractory peripheral T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 22:58:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA